Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. 
The engineered T cells are designed to recognize and destroy cancer cells. Its engineered autologous cell therapy (eACT) technology allows Kite to harness the power of a patient’s own immune system to effectively target and kill cancer cells. This process results in an expanded number of tumor-specific T cells that circulate throughout the body to systemically target and kill cancer cells, including those that have metastasized.

Parent Company
Gilead Sciences
Santa Monica, US
Kite Pharma was founded in 2009 and is headquartered in Santa Monica, US

Kite Pharma Office Locations

Kite Pharma has offices in Santa Monica, El Segundo, Seattle, New York and in 31 other locations
Santa Monica, US (HQ)
2225 Colorado Ave
Amsterdam, NL
408 Science Park
Amsterdam, NL
Science Park 408
Show all (36)

Kite Pharma Financials and Metrics

Kite Pharma Summary

Founding Date

Kite Pharma is a subsidiary of Gilead Sciences

Kite Pharma Financials

Kite Pharma's revenue was reported to be $22.2 m in FY, 2016
USDFY, 2015FY, 2016


17.3 m22.2 m

Revenue growth, %


R&D expense

76.4 m197.9 m

General and administrative expense

44.2 m97.4 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


5.1 m5.1 m4.8 m7.3 m9.8 m10.1 m

R&D expense

9.3 m16.6 m21.7 m34.4 m47.4 m57.3 m65.9 m70.9 m

General and administrative expense

9.2 m9.8 m11.1 m16.5 m23.5 m25 m35.8 m41.1 m

Operating expense total

18.4 m26.4 m32.9 m50.9 m70.9 m82.3 m101.7 m112 m
USDFY, 2014FY, 2015FY, 2016


392.8 m114.6 m


286 k16.4 m13 m

Current Assets

631.1 m427.4 m


30.1 m44.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


283.9 m263.2 m173 m199.6 m170.2 m128.8 m565.2 m147.8 m

Current Assets

435 m403.3 m381.5 m592.5 m541.6 m491.1 m819.2 m798.3 m


4.3 m11.3 m20.3 m40.5 m42.5 m43.5 m46.2 m49.7 m


24.7 m25.8 m26.1 m26.4 m25.8 m26.1 m24.8 m26.6 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(101.7 m)(267.1 m)

Depreciation and Amortization

4.6 m10.6 m


1.3 m(14.8 m)3.3 m

Accounts Payable

2.3 m4.5 m2.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(15.1 m)(20.9 m)(27.4 m)(43.9 m)(64.3 m)(73.9 m)(90.4 m)

Accounts Payable

2.8 m1 m5.6 m4.5 m5.1 m9.6 m6.8 m11.3 m13.2 m
Show all financial metrics

Kite Pharma's Web-traffic and Trends

Kite Pharma Online and Social Media Presence

Kite Pharma News and Updates

Confirmed: Gilead to acquire Kite Pharma for $11.9bn

Shares in Kite Pharma, a US pharmaceuticals firm, have rocketed more than 16 per cent in pre-market trading after reports that it is being acquired. Gilead Sciences has confirmed it has offered $11.9bn (£9.2bn) for the company, in a deal first reported by the Wall Street Journal, $180 per share a…

Kite Pharma's ASCO ads aim to prep docs on CAR-T ahead of FDA approval

Drugmakers put up plenty of ads at ASCO, but only one campaign covered a class of meds that isn't even approved yet. That would be Kite Pharma's CAR-T cell therapy promos, designed to highlight the biotech's educational push for the immunotherapy.

Kite Pharma Company Life and Culture

You may also be interested in